Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Enterprise Value (2022 - 2025)

NewAmsterdam Pharma's Enterprise Value history spans 4 years, with the latest figure at -$636.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 23.73% year-over-year to -$636.2 million; the TTM value through Dec 2025 reached -$636.2 million, up 23.73%, while the annual FY2025 figure was -$636.2 million, 23.73% up from the prior year.
  • Enterprise Value for Q4 2025 was -$636.2 million at NewAmsterdam Pharma, up from -$702.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$340.4 million in Q4 2023 and bottomed at -$834.2 million in Q4 2024.
  • The 4-year median for Enterprise Value is -$447.4 million (2022), against an average of -$543.8 million.
  • The largest annual shift saw Enterprise Value increased 23.9% in 2023 before it plummeted 145.03% in 2024.
  • A 4-year view of Enterprise Value shows it stood at -$447.4 million in 2022, then rose by 23.9% to -$340.4 million in 2023, then tumbled by 145.03% to -$834.2 million in 2024, then grew by 23.73% to -$636.2 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Enterprise Value are -$636.2 million (Q4 2025), -$702.9 million (Q3 2025), and -$739.2 million (Q2 2025).